Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

Perrigo (PRGO) reported Q2 2025 adjusted earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59, and revenues of $1.06 billion, falling short of expectations by 2.63% and marking the fourth consecutive revenue miss. Despite these results and the stock's year-to-date underperformance against the S&P 500, Perrigo holds a Zacks Rank #2 (Buy) based on prior favorable estimate revisions, though future price movement remains contingent on management's commentary.

Analysis

Perrigo (PRGO) delivered a mixed quarterly report, characterized by a top- and bottom-line miss against consensus estimates but year-over-year growth in adjusted earnings. The company reported adjusted EPS of $0.57, falling 3.39% short of the $0.59 consensus, though this represents an increase from $0.53 in the prior-year quarter. More concerning is the revenue performance, which at $1.06 billion missed estimates by 2.63% and marked the fourth consecutive quarter of revenue shortfalls, alongside a slight decline from the $1.07 billion reported a year ago. This consistent inability to meet top-line expectations has contributed to the stock's underperformance, with a 3.5% year-to-date gain lagging the S&P 500's 7.1% advance. A key conflict for investors arises from the company's pre-earnings Zacks Rank #2 (Buy), which was based on a favorable trend in estimate revisions. However, this positive signal is now challenged by the actual results and the fact that PRGO operates within the Medical - Products industry, which ranks in the bottom 41% of Zacks industries, suggesting a potential headwind. The sustainability of any positive price action will be highly dependent on management's forthcoming commentary and subsequent revisions to forward estimates.

Key Decisions for Investors

• Investors should scrutinize management's commentary on the earnings call for a clear explanation of the persistent revenue weakness and any concrete strategies to address it, given this is the fourth consecutive top-line miss.
• Monitor analyst estimate revisions closely in the coming days, as the current Zacks #2 (Buy) rating was based on pre-release data and could be at risk of a downgrade following the earnings and revenue miss.
• Given the stock's existing underperformance against the broader market and its operation within a poorly-ranked industry, initiating or adding to positions may carry heightened risk until a clear positive catalyst emerges.